The separation of ipratropium bromide and its related compounds

A molecularly imprinted polymer-based detection platform confirmed through molecular modeling for the highly sensitive and selective analysis of ipratropium bromide

This study presented a new method to design a MIP-based electrochemical sensor that could improve the selective and sensitive detection of ipratropium bromide (IPR). The polymeric film was designed using 2-hydroxyethyl methacrylate (HEMA) as the basic monomer, 2-hydroxy-2-methylpropiophenone as the initiator, ethylene glycol dimethacrylate (EGDMA) as the crosslinking agent, and N-methacryloyl-L-aspartic acid (MAAsp) as the functional monomer. The presence of MAAsp results in the functional groups in imprinting binding sites, while the presence of poly(vinyl alcohol) (PVA) allows the generation of porous materials not only for sensitive sensing but also for avoiding electron transport limitations. Electrochemical characterizations of the changes at each stage of the MIP preparation process were confirmed using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS). In addition, morphological characterizations of the developed sensor were performed using scanning electron microscopy (SEM), attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), and contact angle measurements. Theoretical calculations were also performed to explain/confirm the experimental results better. It was found that the results of the calculations using the DFT approach agreed with the experimental data. The MAAsp-IPR@MIP/GCE sensor was developed using the photopolymerization method, and the sensor surface was obtained by exposure to UV lamp radiation at 365 nm. The improved MIP-based electrochemical sensor demonstrated the ability to measure IPR for standard solutions in the linear operating range of 1.0 × 10-12-1.0 × 10-11 M under optimized conditions. For standard solutions, the limit of detection (LOD) and limit of quantification (LOQ) were obtained as 2.78 × 10-13 and 9.27 × 10-13 M, respectively. The IPR recovery values for the inhalation form were calculated as 101.70 % and 100.34 %, and the mean relative standard deviations (RSD) were less than 0.76 % in both cases. In addition, the proposed modified sensor demonstrated remarkable sensitivity and selectivity for rapid assessment of IPR in inhalation forms. The sensor's unique selectivity is demonstrated by its successful performance even in the presence of IPR impurities.

Mini Review on Forced Degradation Studies on Anti-Epileptic Drugs and Beyond

In this review on the forced degradation studies on anti-epileptic drugs and the development of validated stability-indicating assay methods for drug substances and products at a condition more severe than accelerated condition (i.e. 40 ± 2°C, 75 ± 5% relative humidity), the drug substance and drug product undergo degradation is known as forced or stress degradation. To know about the impurities developed during the storage of drug products in various environmental conditions. The limit of degradation allowable is 5-20%. More than 20% of degradation is abnormal and must be investigated. Any regulatory guidelines do not mention the pH conditions for acid or base hydrolysis, the temperature for thermal degradation or the concentration of the oxidation agent. Only International Conference on Harmonization (ICH) guidelines Q1B photostability stability and states that light sources must be a combination of UV and visible light. The shortcomings of mentioned techniques with appreciation to regulatory necessities are highlighted. A systematic method for the forced degradation studies on anti-epileptic drugs such as "Topiramate, Vigabatrin, Lacosamide, Tiagabine, Levetiracetam and Zonisamide" is discussed. This review helps researchers to get an idea about stability-indicating methods of development and validation for newer antiepileptic drugs and the characteristics of drug products that degrade under specific degradation conditions.

Simultaneous Analysis of Ipratropium Bromide and its Related Substances Using HPLC

Background:

The main goal of process-related substances investigations is to understand how impurities should be controlled during the synthetic or purification process to produce a high-quality drug substance. The simultaneous determination of related substances is a very important factor in the quality control of API and pharmaceutical dosage forms.

Methods:

A new HPLC method was developed for the simultaneous analysis of Ipratropium bromide and its seven related substances. The separation was performed on a waters HPLC ZORBAX Eclipse XDB- C8 column (150 × 4.6 mm, 3.5 μm). The gradient method used mobile phases containing methanol, acetonitrile, trifluoroacetic acid (TFA), water: A: (methanol, acetonitrile, TFA, 500:500:0.3 v/v/v) and B (0.3% TFA in water v/v). The gradient elution conditions were as follows: 0-32.0 min, linear from 10% A to 35% A; 32.0-36.0 min isocratic 35% A; 36.0-42.0 min linear from 35% to 10%A. The wavelength by UV detector was 220 nm and the flow rate was 1.2 mL/min. The injection volume of sample was 20 μL, and the column temperature was 30 ºC. The proposed RP-HPLC method was applied for the determination of seven related substances.

Results:

All standard curves obtained exhibited good linear regression (r > 0.9939) within the tested range. The average recovery rates were in the range of 98.2-102.0% and RSD was less than 2.9% (n = 3). The process-related impurities were not observed in different batches (<0.025% purity).

Conclusion:

The method was applied to determine 7 process-related substances in ipratropium bromide and proved to be robust, linear, repeatable, sensitive, selective and easy to perform. The results are valuable for quality control in the manufacturing of ipratropium bromide.

Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations

Objectives

This study aimed to investigate the relationship between the mechanical properties of anhydrous and monohydrate ipratropium bromide (IB) crystals, their processing behaviour upon air-jet micronisation and aerosolisation performance in dry powder inhaler (DPI) formulations.

Methods

IB monohydrate and anhydrous crystals were produced from seed crystals and supercritical carbon dioxide crystallisation, respectively. Young's modulus of anhydrous and monohydrate IB crystals was determined using nanoindentation. For air-jet micronised crystals, the physicochemical and surface interfacial properties via the cohesive–adhesive balance (CAB) approach were investigated. These data were correlated to in-vitro aerosolisation performance of carrier-based DPI formulations containing either anhydrous or monohydrate IB.

Key findings

Particle size and Young's modulus of both crystals were similar and this was reflected in their similar processing upon micronisation. Particle size of micronised anhydrous and monohydrate crystals were similar. CAB measurements of the micronised particles of monohydrate or anhydrous forms of IB with respect to lactose were 0.70 (R2 = 0.998) and 0.77 (R2 = 0.999), respectively. These data suggested that both samples had similar adhesion to lactose, which correlated with their similar in-vitro aerosolisation performance in DPI formulations.

Conclusions

Monohydrate and anhydrous crystals of IB exhibited similar mechanical properties and interfacial properties upon secondary processing. As a result, the performance of the DPI formulations were similar.

Placement of the nebulizer before the humidifier during mechanical ventilation: Effect on aerosol delivery

BACKGROUND

Therapeutic aerosols are commonly used in mechanically ventilated patients. The position of the nebulizer in the ventilator circuit and the humidification of inhaled gases can influence the efficiency of aerosol delivery. We evaluated the effect of nebulizer position on the pulmonary bioavailability of nebulized ipratropium in ventilated patients without known preexisting respiratory disease.

METHODS

The study included 38 mechanically ventilated and sedated patients after open heart surgery. Ipratropium (500 microg) was delivered by an ultrasonic nebulizer. Patients were randomized into 2 groups: the nebulizer positioned before the heat humidification system (group 1, n = 19) or at the end of the inspiratory limb before the Y-piece (group 2, n = 19). The amount of ipratropium in the urine collected during the 4 hours after drug administration was measured by mass spectrometry.

RESULTS

There were no statistically significant differences in tidal volume or respiratory rate between groups. There were no significant differences between the 2 groups in the amount of drug excreted (group 1 vs 2: 13,237 +/- 2313 pg/mL vs 15,529 +/- 3204 pg/mL) or in pulmonary bioavailability (.9% +/- .1% vs 1.1% +/- .2%).

CONCLUSION

The position of the nebulizer in the ventilatory circuit had no effect on the pulmonary bioavailability of ipratropium.

On-line high-performance liquid chromatography method for analyte quantitation from pressurized metered dose inhalers

A sensitive and rapid, on-line reversed-phase high-performance liquid chromatographic method for quantitation of compounds at low concentrations in pressurized metered dose inhaler (MDI) systems was developed. Traditional methods for the quantitation of compounds in MDI formulations involve the opening of the MDI vial along with sample dilution prior to quantitation. The new method, reported in this study, involves a direct injection from the MDI vial into the needle injector port of a manual injector. Since there is no dilution step involved, this method can be used to quantitate low concentrations of compounds in MDIs with excellent precision. In addition, since the method requires a small injection volume of 5 microl, repeated analyses can be performed in order to generate multiple data points using the same MDI vial. Validation of the method was performed using ethanol-1,1,1,2-tetrafluoroethane (134a)-based MDIs. Beclomethasone dipropionate (BDP), a corticosteroid used for the treatment of asthma, was used as a model compound. Phase separation studies were conducted to investigate the miscibility of the ethanol-134a mixtures with different mobile phase solvent compositions. For the MDI systems in this study, an acetonitrile-water (90:10, v/v) mobile phase at a flow rate of 0.9 ml/min was found to give acceptable chromatography for BDP on a Apollo C18 5 microm, 150 mm x 4.6 mm column (Alltech Associates, Deerfield, IL, USA). Ultraviolet detection was done at 240 nm and the retention time of BDP was 2.7 min. The on-line HPLC method was characterized to be accurate, precise, sensitive, and specific.

An overview of the recent trends in development of HPLC methods for determination of impurities in drugs

An extensive survey of the literature published in various analytical and pharmaceutical chemistry related journals has been conducted and the high-performance liquid chromatography (HPLC) methods which were developed and used for determination of process-related impurities in drugs have been reviewed. This review covers the time period from 1995 to 2001 during which around 450 analytical methods including all types of chromatographic and hyphenated techniques were reported. HPLC with UV detection was found to be the technique of choice for many workers and more than 200 methods were developed using LC-UV alone. A critical analysis of the reported data has been carried out and the present state-of-art of HPLC for determination of impurities of analgesic, antibiotic, anti-viral, anti-hypertensive, anti-depressant, gastro-intestinal and anti-neoplastic agents has been discussed.

Development of validated stability-indicating assay methods--critical review

This write-up provides a review on the development of validated stability-indicating assay methods (SIAMs) for drug substances and products. The shortcomings of reported methods with respect to regulatory requirements are highlighted. A systematic approach for the development of stability-indicating methods is discussed. Critical issues related to development of SIAMs, such as separation of all degradation products, establishment of mass balance, stress testing of formulations, development of SIAMs for combination products, etc. are also addressed. The applicability of pharmacopoeial methods for the analysis of stability samples is discussed. The requirements of SIAMs for stability study of biotechnological substances and products are also touched upon.